Can You Get Mounjaro on the NHS in the UK?
A clear guide to current NHS access for tirzepatide, including type 2 diabetes use, NHS weight-management rollout, who may be considered, and why access still varies by pathway and local service.
On this page
Many people assume the question is a simple yes or no. It is not. The real question is which NHS pathway you are asking about. Mounjaro may be used on the NHS for some adults with type 2 diabetes, and it is also now part of the NHS conversation around obesity treatment. But those are not the same pathway, and they do not currently work in the same way.
Current NHS status
Tirzepatide has a current NICE treatment appraisal for type 2 diabetes, and NICE has also published guidance recommending tirzepatide as an option for certain adults with overweight or obesity alongside lifestyle support. In England, NHS England has issued interim commissioning guidance for obesity implementation, which means access is being introduced in a structured and prioritised way rather than as a simple immediate national free-for-all.
NHS access for type 2 diabetes
If you have type 2 diabetes, tirzepatide may be considered as part of NHS diabetes treatment where standard criteria are met. NICE guidance for type 2 diabetes is more specific than many people realise. It is not simply a case of having diabetes and asking for Mounjaro.
What clinicians usually look at
- Whether your blood sugar remains insufficiently controlled.
- Which diabetes medicines you have already tried and how you tolerated them.
- Your BMI and whether obesity-related medical problems are part of the picture.
- Whether tirzepatide fits the relevant diabetes treatment sequence and local prescribing rules.
- Whether there are any safety reasons not to prescribe it.
What this means in practice
People with type 2 diabetes may be offered tirzepatide through NHS care, but only where it fits the NHS pathway and the local prescriber agrees it is appropriate. Some people will be managed entirely in primary care, while others may be discussed through a specialist diabetes service.
NHS access for obesity and weight management
This is the part that causes the most confusion. Tirzepatide is now part of the NHS weight-management pathway, but access for obesity is being phased and prioritised. That means the answer is no longer “not available at all”, but it is also not “widely available to everyone who wants it”.
What may make NHS obesity access relevant
- BMI at or above the threshold used in NICE obesity guidance.
- At least 1 relevant weight-related comorbidity.
- Participation in reduced-calorie diet and physical activity support.
- Access to the local NHS route offering tirzepatide within the current rollout phase.
What often causes misunderstanding
- Assuming every GP can prescribe it immediately for weight loss.
- Assuming meeting NICE criteria guarantees immediate supply.
- Confusing NHS rollout with private online prescribing.
- Ignoring local wraparound-care and referral requirements.
In obesity treatment, NHS England has been clear that rollout needs service capacity, prioritisation, and wraparound support. In plain English, that means some patients with the highest clinical need are being seen first, and some people who appear eligible on paper may still need to wait or may be told the local pathway is not yet open to them.
Who may be considered
The exact route depends on whether you are discussing type 2 diabetes management or obesity management. For obesity, NICE guidance is framed around adults with BMI 35 or above and at least 1 weight-related comorbidity, with the medicine used alongside diet and physical-activity support. For type 2 diabetes, NICE diabetes guidance uses a separate treatment-pathway approach rather than a simple “everyone with diabetes qualifies” model.
| Pathway | Main NHS framing | What usually matters |
|---|---|---|
| Type 2 diabetes | Treatment option within NHS diabetes care | Current control, previous medicines, safety, BMI context, local prescribing pathway |
| Obesity / weight management | NICE-recommended but phased NHS rollout | BMI, comorbidity, local service availability, prioritisation, wraparound support |
How to ask about NHS access
If you think NHS access may be relevant, do not just ask “Can I have Mounjaro?” Ask the better question: “Does tirzepatide fit my NHS treatment pathway, and is it available through our local service?”
Book a review
Ask for a medication or condition review with your GP, diabetes team, or weight-management service depending on why tirzepatide is being considered.
Be clear about the reason
Say whether the discussion is about type 2 diabetes management, NHS obesity treatment, or both. These pathways are related but not identical.
Ask about the local route
Find out whether your local NHS area is offering tirzepatide through primary care, specialist services, or a phased referral model.
Ask what criteria apply locally
That may include BMI, relevant conditions, previous treatment history, current blood results, or service-based prioritisation.
NHS cost vs private cost
If you receive tirzepatide on the NHS in England, the usual prescription charge is £9.90 per item, unless you are exempt. A prescription prepayment certificate can reduce overall costs for people who need multiple items over time.
NHS cost in England
- £9.90 per item at the current standard charge.
- 3-month PPC: £32.05.
- 12-month PPC: £114.50.
- Exemptions may apply depending on your circumstances.
Private route
- Private prescribing is usually much more expensive.
- Costs vary by provider, dose, consultation model, and delivery.
- Private access is often faster, but not free at the point of use.
For many people, the real appeal of NHS access is not just the lower monthly cost. It is the difference between a medicine being financially sustainable long term and not.
Why access can still vary
- Different pathways: diabetes care and obesity care are not the same route.
- Phased implementation: obesity rollout is being introduced in stages.
- Local service setup: some areas have clearer routes than others.
- Capacity and prioritisation: not everybody can be seen at once.
- Clinical review: meeting broad criteria does not remove the need for individual assessment.
If you are told no
A “no” can mean different things. It may mean you do not meet the clinical pathway. It may mean your local route is not yet offering tirzepatide for obesity. It may mean another treatment step should be tried first. Or it may simply mean your case needs a different referral route.
Useful next steps
- Ask why the answer is no.
- Ask whether the issue is clinical suitability, local availability, or pathway stage.
- Ask whether another NHS route, specialist review, or follow-up review is appropriate.
- If NHS access is not currently available, compare legitimate private options carefully rather than guessing.
Need a fallback option?
If NHS access is not available through your local route, compare current private options carefully and use NHS information only as one part of the decision.
Frequently asked questions
Can you get Mounjaro on the NHS for type 2 diabetes?
Yes, tirzepatide may be used on the NHS for some adults with type 2 diabetes where it fits the relevant treatment pathway and local prescribing decisions.
Can you get Mounjaro on the NHS for weight loss?
NHS access for obesity and weight management now exists in principle, but rollout is phased and prioritised. It is not yet a simple immediate route for everyone who appears eligible on paper.
Does meeting NICE criteria guarantee access?
No. NICE guidance matters, but local NHS rollout, referral pathways, wraparound care, prioritisation, and capacity still affect real-world access.
Can any GP prescribe it for obesity right away?
Not necessarily. In many areas the route depends on local service setup and may involve staged access, referral, or structured support rather than simple immediate GP prescribing.
How much is it on the NHS in England?
The current standard NHS prescription charge is £9.90 per item in England, unless you are exempt. A prescription prepayment certificate may reduce costs for some people.
What if my local NHS service does not offer it yet?
Ask whether there is another referral route, whether rollout is planned locally, and whether a later review is appropriate. If not, use legitimate private comparisons carefully.